Is NRX Pharmaceuticals Inc halal to invest in?

According to Musaffa's Shariah screening methodology, NRX Pharmaceuticals Inc (NRXP) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is NRX Pharmaceuticals Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes NRX Pharmaceuticals Inc using these criteria to determine its compliance status.

Can Muslims buy shares of NRX Pharmaceuticals Inc?

Muslim investors may consider investing in NRX Pharmaceuticals Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is NRX Pharmaceuticals Inc classified as NOT HALAL?

Musaffa determines the Shariah status of NRX Pharmaceuticals Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for NRX Pharmaceuticals Inc updated?

The Shariah compliance status of NRX Pharmaceuticals Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like NRX Pharmaceuticals Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of NRX Pharmaceuticals Inc?

You can check the latest Shariah compliance status of NRX Pharmaceuticals Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

NRXP Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: March 25, 2026

Report Source: 2025 Annual Report

NRX Pharmaceuticals Inc. Stock Analysis NRXP

United States Health Care Micro Cap Report: 2025 Annual

NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is headquartered in Wilmington, Delaware and currently employs 29 full-time employees. The company went IPO on 2017-11-20. The company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal Ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal depression. Its subsidiary, HOPE Therapeutics, Inc., is a healthcare delivery company that is building a network of interventional psychiatry clinics.

Key Statistics of NRX Pharmaceuticals Inc (NRXP)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$3.23$3.50

Today's Open

$3.25

Volume

2.25M

P/E Ratio (TTM)

52 Week Range

$1.62$3.84

Market Cap

100.53M

Avg. Volume

1.25M

Dividend Yield

Financial Metrics & Statements of NRX Pharmaceuticals Inc (NRXP)

FAQ's for NRX Pharmaceuticals Inc (NRXP)

According to Musaffa’s Shariah screening methodology, NRX Pharmaceuticals Inc (NRXP) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.